SCHEMBL3660180

SCHEMBL3660180

CCC(=O)N1CCCc2ccccc21

nearest known ligand 0.72

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.69
SMN1; SMN2 Q16637 2/20 0.68
ALDH1A1 P00352 4/20 0.67
TSHR P16473 3/20 0.67
LMNA P02545 1/20 0.67
MAPK1 P28482 1/20 0.67
NPSR1 Q6W5P4 1/20 0.67
KMT2A Q03164 3/20 0.65
KDM4E B2RXH2 1/20 0.63
POLB P06746 1/20 0.63
PKM P14618 1/20 0.63
GAA P10253 1/20 0.62
MEN1 O00255 2/20 0.61
GRM7 Q14831 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29520673 1.00 NOTUM (0.69) NOTUMSMN1; SMN2ALDH1A1TSHRLMNA
Hydrochloric Acid SCHEMBL29520826 0.98 NOTUM (0.67) NOTUMSMN1; SMN2ALDH1A1TSHRLMNA
Hydrochloric Acid SCHEMBL29521106 0.98 NOTUM (0.67) NOTUMSMN1; SMN2ALDH1A1TSHRLMNA
SCHEMBL24925819 0.95 ALDH1A1 (0.62) NOTUMSMN1; SMN2ALDH1A1TSHRLMNA
SCHEMBL5006023 0.90 TSHR (0.75) NOTUMSMN1; SMN2ALDH1A1TSHRMAPK1
SCHEMBL711283 0.88 TSHR (0.67) NOTUMSMN1; SMN2ALDH1A1TSHRMAPK1
SCHEMBL29522633 0.88 TSHR (0.67) NOTUMSMN1; SMN2ALDH1A1TSHRMAPK1
SCHEMBL1545217 0.85 SMN1; SMN2 (0.70) NOTUMSMN1; SMN2ALDH1A1TSHRMAPK1
SCHEMBL9278163 0.84 SMN1; SMN2 (0.73) NOTUMSMN1; SMN2ALDH1A1TSHRLMNA
SCHEMBL3089154 0.84 SMN1; SMN2 (0.68) NOTUMSMN1; SMN2ALDH1A1TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205559-A1 RENIN INHIBITORS Cadila Healthcare Limited (IN) 2010-07-14 EP claimed
WO-2009087649-A1 RENIN INHIBITORS CADILA HEALTHCARE LIMITED (IN) 2009-07-16 WO claimed
US-11358936-B2 Lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. (US) 2022-06-14 US disclosed
US-20210171465-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2021-06-10 US disclosed
EP-3265445-B1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2021-05-05 EP disclosed
EP-3778573-A1 COMPOUND WITH ANTICANCER ACTIVITY Kyowa Kirin Co., Ltd. (JP) 2021-02-17 EP disclosed
US-20170020858-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES INC (US) 2017-01-26 US disclosed
WO-2016144702-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2016-09-15 WO disclosed
US-20150299225-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2015-10-22 US disclosed
WO-2011143772-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-24 WO disclosed
WO-2011091040-A1 USE OF ISOXAZOLINE COMPOUNDS AND COMPOSITIONS IN BLADDER CANCER CYTOKINE PHARMASCIENCES, INC. (US) 2011-07-28 WO disclosed
EP-1130017-B1 Azole derivatives and their use as superoxide radical inhibitors OTSUKA PHARMA CO LTD (JP) 2005-06-15 EP disclosed
EP-0934937-B1 Azole derivatives as superoxide radical inhibitor OTSUKA PHARMA CO LTD (JP) 2002-02-27 EP disclosed
US-RE37556-E1 (ALKOXYPHENYL)THIAZOLE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2002-02-19 US disclosed
EP-1130017-A2 Azole derivatives and their use as superoxide radical inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2001-09-05 EP disclosed
US-6080764-A PROTECTING VARIOUS TISSUE CELLS FROM DISTURBANCES ASSOCIATED WITH ISCHEMIA AND BLOOD REPERFUSION IN HEART, BRAIN, KIDNEY, LUNG AND DIGESTIVE TRACT BY INHIBITING SUPEROXIDE-RELEASE BY NEUTROPHILIC LEUKOCYTES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2000-06-27 US disclosed
EP-0934937-A1 Azole derivatives as superoxide radical inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1999-08-11 EP disclosed
US-5677319-A THIAZOLE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-10-14 US disclosed
US-5643932-A PREVENTS CELL DAMAGE AFTER ISCHEMIA AND RE-PERFUSION, SUBSTITUTED THIAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-07-01 US disclosed
EP-0513387-A1 ACTIVE OXYGEN INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11358936-B2 Lysyl oxidase-like 2 inhibitors and uses thereof LOXL2, LOXL1, LOX NOTUM 590/4885SMN1; SMN2 1966/4885ALDH1A1 982/4885
US-20210171465-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX NOTUM 590/4885SMN1; SMN2 1966/4885ALDH1A1 982/4885
US-20170020858-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION TRPV3, TRPV1, TRPV4 NOTUM 3883/4885SMN1; SMN2 2219/4885ALDH1A1 3074/4885
US-20150299225-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION TRPV3, TRPV1, TRPV4 NOTUM 3883/4885SMN1; SMN2 2219/4885ALDH1A1 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.